Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
TMO Stock Summary
Top 10 Correlated ETFs
TMO
In the News
Thermo Fisher Scientific (TMO) Exceeds Market Returns: Some Facts to Consider
In the closing of the recent trading day, Thermo Fisher Scientific (TMO) stood at $579.37, denoting a +1.85% change from the preceding trading day.
Thermo Fisher Scientific (TMO) Falls More Steeply Than Broader Market: What Investors Need to Know
Thermo Fisher Scientific (TMO) concluded the recent trading session at $568.82, signifying a -0.83% move from its prior day's close.
Thermo Fisher Scientific (TMO) Stock Declines While Market Improves: Some Information for Investors
In the closing of the recent trading day, Thermo Fisher Scientific (TMO) stood at $580.05, denoting a -0.46% change from the preceding trading day.
Thermo Fisher Scientific (TMO) Stock Falls Amid Market Uptick: What Investors Need to Know
Thermo Fisher Scientific (TMO) reachead $580.05 at the closing of the latest trading day, reflecting a -0.7% change compared to its last close.
3 Nanotechnology Stocks That Could Soar as the Technology Advances
A rapidly growing field, nanotechnology deals with the manipulation of matter at the atomic and molecular scale. This allows for the creation of materials and technological applications beyond the size of standard microelectronics or chemical structures.
Thermo Fisher Scientific Inc. (TMO) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to Thermo Fisher (TMO). This makes it worthwhile to examine what the stock has in store.
Calls of the Day: Regeneron, Thermo Fisher, Darden Restaurants and Nucor
The Investment Committee debate the latest calls of the day on a number of stocks.
Thermo Fisher Scientific (TMO) Stock Falls Amid Market Uptick: What Investors Need to Know
In the latest trading session, Thermo Fisher Scientific (TMO) closed at $597.25, marking a -0.36% move from the previous day.
Thermo Fisher (TMO) Unveils CorEvitas Clinical Registry in GPP
Thermo Fisher's (TMO) new CorEvitas clinical registry addresses an unmet need for real-world evidence related to the clinical and patient-reported outcomes of patients with GPP.
Thermo Fisher Scientific (TMO) Exceeds Market Returns: Some Facts to Consider
Thermo Fisher Scientific (TMO) reachead $591.50 at the closing of the latest trading day, reflecting a +1.18% change compared to its last close.
TMO Financial details
TMO Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 63.86 | 81.36 | 99.52 | 114.58 | 111.03 | |
Net income per share | 9.24 | 16.1 | 19.61 | 17.73 | 15.53 | |
Operating cash flow per share | 12.43 | 20.93 | 24.22 | 23.35 | 21.78 | |
Free cash flow per share | 10.12 | 17.21 | 17.82 | 17.63 | 17.95 | |
Cash per share | 6 | 26.07 | 11.36 | 21.74 | 20.92 | |
Book value per share | 74.19 | 87.14 | 103.54 | 112.19 | 121.05 | |
Tangible book value per share | -25.13 | -10.63 | -53.54 | -37.06 | -35.88 | |
Share holders equity per share | 74.19 | 87.14 | 103.54 | 112.19 | 121.05 | |
Interest debt per share | 46.1 | 56.38 | 89.39 | 89.54 | 94.02 | |
Market cap | 129.95B | 184.45B | 262.89B | 215.87B | 204.88B | |
Enterprise value | 145.3B | 195.86B | 293.29B | 241.83B | 231.72B | |
P/E ratio | 35.16 | 28.93 | 34.03 | 31.06 | 34.18 | |
Price to sales ratio | 5.09 | 5.73 | 6.7 | 4.81 | 4.78 | |
POCF ratio | 26.13 | 22.25 | 27.55 | 23.58 | 24.37 | |
PFCF ratio | 32.11 | 27.07 | 37.45 | 31.24 | 29.58 | |
P/B Ratio | 4.38 | 5.35 | 6.44 | 4.91 | 4.39 | |
PTB ratio | 4.38 | 5.35 | 6.44 | 4.91 | 4.39 | |
EV to sales | 5.69 | 6.08 | 7.48 | 5.38 | 5.41 | |
Enterprise value over EBITDA | 21.98 | 19.2 | 24.11 | 20.06 | 21.61 | |
EV to operating cash flow | 29.22 | 23.63 | 30.73 | 26.42 | 27.57 | |
EV to free cash flow | 35.9 | 28.74 | 41.78 | 34.99 | 33.45 | |
Earnings yield | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | |
Free cash flow yield | 0.03 | 0.04 | 0.03 | 0.03 | 0.03 | |
Debt to equity | 0.6 | 0.63 | 0.85 | 0.78 | 0.75 | |
Debt to assets | 0.3 | 0.32 | 0.36 | 0.35 | 0.35 | |
Net debt to EBITDA | 2.32 | 1.12 | 2.5 | 2.15 | 2.5 | |
Current ratio | 1.92 | 2.13 | 1.5 | 1.48 | 1.75 | |
Interest coverage | 6.8 | 14.09 | 18.71 | 11.56 | 5.32 | |
Income quality | 1.35 | 1.3 | 1.23 | 1.32 | 1.4 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0.08 | 0.05 | 0.05 | 0.07 | 0.09 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0.04 | 0.04 | 0.04 | 0.03 | 0.03 | |
Intangibles to total assets | 0.68 | 0.56 | 0.65 | 0.6 | 0.61 | |
Capex to operating cash flow | -0.19 | -0.18 | -0.26 | -0.25 | -0.18 | |
Capex to revenue | -0.04 | -0.05 | -0.06 | -0.05 | -0.03 | |
Capex to depreciation | -0.41 | -0.63 | -0.97 | -0.66 | -0.43 | |
Stock based compensation to revenue | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
Graham number | 124.19 | 177.66 | 213.72 | 211.55 | 205.67 | |
ROIC | 0.09 | 0.12 | 0.11 | 0.07 | 0.06 | |
Return on tangible assets | 0.2 | 0.21 | 0.23 | 0.18 | 0.16 | |
Graham Net | -52.27 | -43.79 | -102.63 | -88.25 | -90.93 | |
Working capital | 5.7B | 11.65B | 6.68B | 8.22B | 10.58B | |
Tangible asset value | -10.05B | -4.21B | -21.09B | -14.53B | -13.85B | |
Net current asset value | -16.81B | -12.58B | -34.03B | -27.78B | -27.3B | |
Invested capital | 0.6 | 0.63 | 0.85 | 0.78 | 0.75 | |
Average receivables | 4.77B | 5.71B | 7.71B | 9.19B | 8.82B | |
Average payables | 1.77B | 2.05B | 2.52B | 3.12B | 3.13B | |
Average inventory | 3.19B | 3.7B | 4.54B | 5.34B | 5.36B | |
Days sales outstanding | 70.77 | 73.32 | 83.27 | 76.61 | 70.02 | |
Days payables outstanding | 51.1 | 50.52 | 55.14 | 48.56 | 37.94 | |
Days of inventory on hand | 89.69 | 93.59 | 97.15 | 80.91 | 67.21 | |
Receivables turnover | 5.16 | 4.98 | 4.38 | 4.76 | 5.21 | |
Payables turnover | 7.14 | 7.22 | 6.62 | 7.52 | 9.62 | |
Inventory turnover | 4.07 | 3.9 | 3.76 | 4.51 | 5.43 | |
ROE | 0.12 | 0.18 | 0.19 | 0.16 | 0.13 | |
Capex per share | -2.32 | -3.72 | -6.4 | -5.72 | -3.83 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-12-31 | 2023-04-01 | 2023-07-01 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 29.28 | 27.75 | 27.69 | 27.39 | 28.13 | |
Net income per share | 4.03 | 3.34 | 3.53 | 4.44 | 4.21 | |
Operating cash flow per share | 8.92 | 1.89 | 3.99 | 6.25 | 9.62 | |
Free cash flow per share | 7.51 | 0.7 | 3.25 | 5.39 | 8.57 | |
Cash per share | 21.8 | 9.02 | 8.12 | 15.94 | 20.87 | |
Book value per share | 112.48 | 109.47 | 113.35 | 117.43 | 120.73 | |
Tangible book value per share | -37.15 | -48.39 | -43.51 | -39.4 | -35.78 | |
Share holders equity per share | 112.48 | 109.47 | 113.35 | 117.43 | 120.73 | |
Interest debt per share | 88.6 | 91.79 | 88.46 | 92.22 | 89.22 | |
Market cap | 215.32B | 222.48B | 201.4B | 195.38B | 205.42B | |
Enterprise value | 241.28B | 254.25B | 232.27B | 224.51B | 232.26B | |
P/E ratio | 34.16 | 43.15 | 36.99 | 28.48 | 31.51 | |
Price to sales ratio | 18.81 | 20.77 | 18.84 | 18.48 | 18.87 | |
POCF ratio | 61.75 | 305.18 | 130.78 | 80.94 | 55.17 | |
PFCF ratio | 73.31 | 820.96 | 160.35 | 93.84 | 61.91 | |
P/B Ratio | 4.9 | 5.26 | 4.6 | 4.31 | 4.4 | |
PTB ratio | 4.9 | 5.26 | 4.6 | 4.31 | 4.4 | |
EV to sales | 21.07 | 23.74 | 21.73 | 21.23 | 21.34 | |
Enterprise value over EBITDA | 81.82 | 96.53 | 83.13 | 73.35 | 125.27 | |
EV to operating cash flow | 69.2 | 348.77 | 150.83 | 93.01 | 62.38 | |
EV to free cash flow | 82.15 | 938.21 | 184.93 | 107.84 | 70 | |
Earnings yield | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
Free cash flow yield | 0.01 | 0 | 0.01 | 0.01 | 0.02 | |
Debt to equity | 0.78 | 0.83 | 0.77 | 0.78 | 0.75 | |
Debt to assets | 0.35 | 0.37 | 0.36 | 0.36 | 0.35 | |
Net debt to EBITDA | 8.8 | 12.06 | 11.05 | 9.52 | 14.48 | |
Current ratio | 1.48 | 1.27 | 1.42 | 1.63 | 1.75 | |
Interest coverage | 6.92 | 5.21 | 4.84 | 5.19 | -4.75 | |
Income quality | 2.22 | 0.56 | 1.13 | 1.42 | 2.28 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0.07 | 0.09 | 0.1 | 0.08 | 0.08 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | |
Intangibles to total assets | 0.6 | 0.65 | 0.65 | 0.63 | 0.61 | |
Capex to operating cash flow | -0.16 | -0.63 | -0.18 | -0.14 | -0.11 | |
Capex to revenue | -0.05 | -0.04 | -0.03 | -0.03 | -0.04 | |
Capex to depreciation | -0.65 | -0.53 | -0.33 | -0.39 | -0.48 | |
Stock based compensation to revenue | 0.01 | 0.01 | -0.01 | -0.01 | 0.01 | |
Graham number | 101 | 90.69 | 94.83 | 108.35 | 106.97 | |
ROIC | 0.02 | 0.01 | 0.01 | 0.02 | 0.02 | |
Return on tangible assets | 0.04 | 0.04 | 0.04 | 0.05 | 0.04 | |
Graham Net | -88.48 | -100.88 | -96.15 | -91.62 | -90.69 | |
Working capital | 8.22B | 4.33B | 5.88B | 8.93B | 10.58B | |
Tangible asset value | -14.53B | -18.68B | -16.8B | -15.21B | -13.85B | |
Net current asset value | -27.78B | -32.02B | -30.2B | -28.5B | -27.3B | |
Invested capital | 0.78 | 0.83 | 0.77 | 0.78 | 0.75 | |
Average receivables | 9.17B | 9.36B | 9.39B | 9.66B | 9.03B | |
Average payables | 2.93B | 3.09B | 2.61B | 2.47B | 2.69B | |
Average inventory | 5.68B | 5.65B | 5.66B | 5.53B | 5.25B | |
Days sales outstanding | 74.1 | 78.13 | 79.89 | 83.71 | 67.97 | |
Days payables outstanding | 45.31 | 39.12 | 34.49 | 36.73 | 40.45 | |
Days of inventory on hand | 75.51 | 79.19 | 80.49 | 79.15 | 71.66 | |
Receivables turnover | 1.21 | 1.15 | 1.13 | 1.08 | 1.32 | |
Payables turnover | 1.99 | 2.3 | 2.61 | 2.45 | 2.22 | |
Inventory turnover | 1.19 | 1.14 | 1.12 | 1.14 | 1.26 | |
ROE | 0.04 | 0.03 | 0.03 | 0.04 | 0.03 | |
Capex per share | -1.41 | -1.19 | -0.74 | -0.86 | -1.05 |
TMO Frequently Asked Questions
What is Thermo Fisher Scientific Inc. stock symbol ?
Thermo Fisher Scientific Inc. is a US stock , located in Waltham of Ma and trading under the symbol TMO
Is Thermo Fisher Scientific Inc. buy or a sell ?
27 stock analysts have 27 predictions with a medium analyst target price of $636.67. The lowest prediction is $505 and the highest is $711
What is TMO stock prediction ?
What is Thermo Fisher Scientific Inc. stock quote today ?
Thermo Fisher Scientific Inc. stock price is $579.4 today.
Is Thermo Fisher Scientific Inc. stock public?
Yes, Thermo Fisher Scientific Inc. is a publicly traded company.